Table 3.
Univariate analysis for LRRFS
| Variable | 10-Yr LRRFS (%) | p-value |
|---|---|---|
| Age (yr) | ||
| < 40 | 73.2 | 0.01 |
| ≥ 40 | 89 | |
| Type of breast surgery | ||
| Breast conserving surgery | 86.5 | 0.17 |
| Total mastectomy | 82.5 | |
| T stage | ||
| pT1-2 | 84.0 | 0.91 |
| pT3-4 | 89.0 | |
| N stage | ||
| 1 | 85.2 | 0.26 |
| 2 | 80.4 | |
| 3 | 85.4 | |
| Lymph node ratio | ||
| < 0.2 | 84.9 | 0.09 |
| ≥ 0.2 | 83.6 | |
| Histologic grade | ||
| 1 (low) | 100 | < 0.01 |
| 2 (intermediate) | 87.8 | |
| 3 (high) | 77.5 | |
| Resection margin (mm) | ||
| < 2 | 87.4 | < 0.01 |
| ≥ 2 | 69.2 | |
| Biological subtype | ||
| Luminal A | 86.6 | 0.05 |
| Luminal B | 77.4 | |
| HER2-enriched | 81.5 | |
| Triple negative | 88.4 | |
| Radiation field | ||
| No | 79.5 | 0.42 |
| Breast/Chest wall only | 85.7 | |
| Breast/Chest wall+SCL | 84 | |
| Breast/Chest wall+SCL+IMN | 89.1 | |
| Adjuvant trastuzumab | ||
| No | 76 | 0.24 |
| Yes | 91.2 |
LRRFS, locoregional recurrence-free survival; HER2, human epidermal growth factor receptor type 2; SCL, supraclavicular lymph node area; IMN, internal mammary node area.